


column: SLB-5ms, 20 m x 0.18 mm I.D., 0.18 μ m (28564-U)
 oven: 100 °C (1 min.), 35 °C/min. to 290 °C (3 min.),
 40 °C/min. to 360 °C
 inj.: 250 °C
 MSD interface: 325 °C
 scan range: m/z = 40-450
 carrier gas: helium, 1 mL/min., constant
 injection: 0.5 μ L, splitless (1.0 min.)
 liner: 2 mm I.D., straight
 sample: TBDMS derivatives of amino acids,
 each approximately 23 μ g/mL

- | | |
|--|--|
| 1. Alanine; m/z=260, 232, 158 | 14. Aspartic acid; m/z= 418, 390, 316 |
| 2. Glycine; m/z=246, 218 | 15. Hydroxyproline; m/z= 416, 388, 314 |
| 3. Valine; m/z= 288, 260, 186 | 16. Cysteine; m/z= 406, 378 |
| 4. artifact from derivatization | 17. Glutamic acid; m/z= 432, 330, 272 |
| 5. Leucine; m/z=302, 274, 200 | 18. Asparagine; m/z= 417, 302 |
| 6. Isoleucine; m/z=302, 274, 200 | 19. Lysine; m/z= 431, 329, 300 |
| 7. Proline; m/z= 286, 258, 184 | 20. Glutamine; m/z= 431, 357, 329, 299 |
| 8. Asparagine, extra derivative;
m/z= 327, 285, 243 | 21. Histidine; m/z= 459, 440, 338, 196 |
| 9. Glutamine, extra derivative;
m/z= 342, 300, 272 | 22. Tyrosine; m/z= 466, 438, 364, 302 |
| 10. Methionine; m/z= 320, 292, 218 | 23. Tryptophan, extra derivative
m/z= 417, 375, 347, 302, 273 |
| 11. Serine; m/z= 390, 362 | 24. Tryptophan; m/z= 489, 302, 244 |
| 12. Threonine; m/z= 404, 376, 303 | 25. Cystine; m/z=639, 589, 537, 348 |
| 13. Phenylalanine; m/z= 336, 302, 234 | |




column: Nukol, 15 m x 0.53 mm I.D., 0.50 μ m (25326)
 oven: 100 °C, 10 °C/min. to 220 °C
 det.: FID

carrier gas: helium, 30 mL/min.



injection: 0.5 μ L, direct injection

sample: 16 analytes, at various concentrations from 50 to 800 μ g/mL

1. Acetic acid
2. Propionic acid
3. Isobutyric acid
4. Butyric acid
5. Isovaleric acid
6. Valeric acid
7. Isocaproic acid
8. Caproic acid
9. Heptanoic acid
10. Octanoic acid
11. Decanoic acid
12. Dodecanoic acid
13. Tetradecanoic acid
14. Hexadecanoic acid
15. Octadecanoic acid
16. Eicosanoic acid



794-0480



Conditions


column	SP-2380, 30 m x 0.25 mm I.D., 0.20 μ m (24110-U)
oven	275 °C
carrier gas	helium, 20 cm/sec @ 275 °C
sample	alditol acetates, 6 mg/mL in chloroform
injection	1 μ L100:1 split
detector	FID

Peaks

1. Val-Tyr
2. Val-Tyr-Val
3. Meth enkephalin

Peaks

4. Val-4-angiotensin III
5. Angiotensin II, III
6. Leucine enkephalin
7. Angiotensin I



LC_BC0386

Column

Viva C18 (cat.# 9514562)
Dimensions: 150 mm x 2.1 mm ID
Particle Size: 5 µm
Pore Size: 300 Å
Temp.: ambient

Sample

peptide test mix

Inj. Vol.: 20 µL

Mobile Phase

A: 0.08% trifluoroacetic acid in water
B: 0.08% TFA in acetonitrile


Time (min)%B

0.00 10
20 40

Flow: 0.2 mL/min

Detector




UV/Vis @ 214 nm





Peaks
1. Fructose
2. Glucose
3. Sucrose
4. Maltose
5. Lactose


Conc. (mg/mL)
2.0
2.1
4.0
4.5
4.4


Column
Ultra Amino (cat. # 9107365)
Dimensions: 150 mm x 4.6 mm ID
Particle Size: 3 μ m
Pore Size: 100 Å
Temp.: 35 °C
Sample
Diluent: Mobile phase
Inj. Vol.: 20 μ L
Mobile Phase
Flow: Water:acetonitrile (25:75)
0.8 mL/min
Detector
RI
Cell Temp: 35 °C






$$R_f = Y/X \text{ (always } \leq 1)$$








Gel filtration




Hydrophobic interaction



Ion exchange



Affinity



Reversed phase

Affinity Chromatography Principles and Methods, GE Healthcare

Affinity chromatography separates proteins on the basis of a reversible interaction between a protein (or group of proteins) and a specific ligand coupled to a chromatography matrix. The technique is ideal for a capture or intermediate step in a purification protocol and can be used whenever a suitable ligand is available for the protein(s) of interest. With high selectivity, hence high resolution, and high capacity for the protein(s) of interest, purification levels in the order of several thousand-fold with high recovery of active material are achievable. Target protein(s) is collected in a purified, concentrated form.



Matrix: for ligand attachment. Matrix should be chemically and physically inert.



Spacer arm: used to improve binding between ligand and target molecule by overcoming any effects of steric hindrance.



Ligand: molecule that binds reversibly to a specific target molecule or group of target molecules.

Any component can be used as a ligand to purify its respective binding partner. Some typical biological interactions, frequently used in affinity chromatography, are listed below:

- Enzyme □ substrate analogue, inhibitor, cofactor.
- Antibody □ antigen, virus, cell.
- Lectin □ polysaccharide, glycoprotein, cell surface receptor, cell.
- Nucleic acid □ complementary base sequence, histones, nucleic acid polymerase, nucleic acid binding protein.
- Hormone, vitamin □ receptor, carrier protein.
- Glutathione □ glutathione-S-transferase or GST fusion proteins.
- Metal ions □ Poly (His) fusion proteins, native proteins with histidine, cysteine and/or tryptophan residues on their surfaces.



1. Affinity medium is equilibrated in binding buffer.



2. Sample is applied under conditions that favor specific binding of the target molecule(s) to a complementary binding substance (the ligand). Target substances bind specifically, but reversibly, to the ligand and unbound material washes through the column.




3. Target protein is recovered by changing conditions to favor elution of the bound molecules. Elution is performed specifically, using a competitive ligand, or non-specifically, by changing the pH, ionic strength or polarity. Target protein is collected in a purified, concentrated form.




4. Affinity medium is re-equilibrated with binding buffer.

Affinity Chromatography Principles and Methods, GE Healthcare



Affinity Chromatography Principles and Methods, GE Healthcare



Method 1



The simplest case. A change of buffer composition elutes the bound substance without harming either it or the ligand.

Method 2


Extremes of pH or high concentrations of chaotropic agents are required for elution, but these may cause permanent or temporary damage.

Methods 3 and 4

Specific elution by addition of a substance that competes for binding. These methods can enhance the specificity of media that use group-specific ligands.




Affinity Chromatography Principles and Methods, GE Healthcare




Gel Filtration Principles and Methods, GE Healthcare

D)



Gel Filtration Principles and Methods, GE Healthcare



Column:	Superdex 200 HR 10/30 (V_t : 24 ml)	
Sample:	M_r	Conc. (mg/ml)
Thyroglobulin	669 000	3
Ferritin	440 000	0.7
IgG	150 000	3
Transferrin	81 000	3
Ovalbumin	43 000	3
Myoglobin	17 600	2
Vitamin B12	1 355	0.5
Total		15.2

Sample load:

A) 25 μl ($0.1\% \times V_t$)

B) 250 μl ($1\% \times V_t$)


C) 1000 μl ($4.2\% \times V_t$)

Buffer:


0.05 M sodium phosphate,
0.15 M NaCl, pH 7.0

Flow rate:

1.0 ml/min (76.4 cm/h)




Gel Filtration Principles and Methods, GE Healthcare




Gel Filtration Principles and Methods, GE Healthcare


Columns: HiPrep™ 16/10 Sephacryl S-100 HR
HiPrep 16/10 Sephacryl S-200 HR
HiPrep 16/10 Sephacryl S-300 HR
Sample: IgG, ovalbumin, cytochrome C, 1:2:1
Sample load: 2.4 ml (2% × V_t)
Total sample load: 8 mg
Buffer: 50 mM NaPO₄, 0.15 M NaCl, 0.02% NaN₃, pH 7.0



Gel Filtration Principles and Methods, GE Healthcare




“IEX chromatography takes advantage of the fact that the relationship between net surface charge and pH is unique for a specific protein. A protein that has no net charge at a pH equivalent to its isoelectric point (pI) will not interact with a charged medium.”




Equilibration





IEX medium equilibrated with start buffer.




Sample application



Oppositely-charged proteins bind to ionic groups of the IEX medium, becoming concentrated on the column. Uncharged proteins, or those with the same charge as the ionic groups, elute during or just after sample application.




Elution 1





Increasing ionic strength (using a gradient) displaces bound proteins as ions in the buffer compete for binding sites.


Elution 2




Further increases in ionic strength displace proteins that are more highly charged (more tightly bound)




Elution 3



Wash



Final high ionic strength wash removes any ionically bound proteins before re-equilibration




Ion Exchange Chromatography & Chromatofocusing Principles and Methods, GE Healthcare

Rapid exchange of counter-ions, typically Na^+ or Cl^- , and solute molecules


Rapid diffusion

Small bead size
Uniform pore size distribution




Even buffer flow distribution
Uniform packing
Narrow particle size distribution

Ion Exchange Chromatography & Chromatofocusing Principles and Methods, GE Healthcare



Ion Exchange Chromatography & Chromatofocusing Principles and Methods, GE Healthcare



Ion Exchange Chromatography &
Chromatofocusing Principles and Methods,
GE Healthcare




Fig. 10b. Typical IEX separation using step elution (25–30 column volumes).

Table 1. Ion exchange matrices.

	Form	Mean particle size
MiniBeads™	Polystyrene/divinyl benzene	3 µm
MonoBeads™	Polystyrene/divinyl benzene	10 µm
SOURCE 15	Polystyrene/divinyl benzene	15 µm
SOURCE 30	Polystyrene/divinyl benzene	30 µm
Sepharose High Performance	Agarose 6%	34 µm
Sepharose Fast Flow	Agarose 6%	90 µm
Sepharose 4 Fast Flow	Agarose 4%	90 µm
Sepharose XL	Agarose 6%, dextran chains coupled to agarose	90 µm
Sepharose Big Beads	Agarose 6%	200 µm




Table 2. Functional groups used on ion exchangers.

Anion exchangers		Functional group
Quaternary ammonium (Q)	strong	$-O-CH_2N^+(CH_3)_3$
Diethylaminoethyl (DEAE)*	weak	$-O-CH_2CH_2N^+H(CH_2CH_3)_2$
Diethylaminopropyl (ANX)*	weak	$-O-CH_2CHOHCH_2N^+H(CH_2CH_3)_2$
Cation exchangers		Functional group
Sulfopropyl (SP)	strong	$-O-CH_2CHOHCH_2OCH_2CH_2CH_2SO_3^-$
Methyl sulfonate (S)	strong	$-O-CH_2CHOHCH_2OCH_2CHOHCH_2SO_3^-$
Carboxymethyl (CM)	weak	$-O-CH_2COO^-$